Sinovac recruits Phase III hepatitis A study; registers EV71 bridging trial in Vietnam

Sinovac Biotech had two registry updates this week, one active recruitment status and one new trial listing.

• A Phase III trial of Sinovac's Healive hepatitis A vaccine is recruiting. The study is an open-label, single arm design combined with a randomized, double-blind, active-controlled design assessing two dosage specifications of Healive, enrolling 680 healthy participants aged 1 year and above, split between an adult dose group of 200 and a pediatric dose group of 480.¹ The pediatric group is compared against Sanofi's Avaxim vaccine.¹
• Sinovac's EV71 vaccine bridging study in Vietnamese children is not yet recruiting. The trial is a single-armed bridging clinical trial planning to enroll approximately 320 healthy participants who will receive two doses of the vaccine on a 0 and 30-day schedule.² Its primary objective is to assess the seroconversion rate of neutralizing antibodies 30 days after the second dose.²